Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB (“Medivir” or “the Company”) has renegotiated its agreement with...
Read moreThe shareholders of Medivir AB, reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the extraordinary...
Read moreThe Board of Directors of Medivir AB (publ) (”Medivir” or “the Company”) has today resolved to carry out a rights issue...
Read moreJuly – September Significant events during the quarter In July, a research collaboration was initiated with the Drug Discovery and Development...
Read moreStockholm — Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Dr. Tom Morris as interim Chief Medical Officer effective...
Read moreApril – June Significant events during the quarter Following the positive opinion given by the European Medicines Agency (EMA), the European...
Read moreStockholm — Medivir AB (Nasdaq Stockholm: MVIR) announced today that Dr. Yilmaz Mahshid will assume his position as CEO on September...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered a research collaboration with the Drug Discovery...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the European Commission, in accordance with the opinion from the...
Read moreStockholm — Medivir AB (Nasdaq Stockholm: MVIR) today announced that its Board of Directors has appointed Yilmaz Mahshid as the new...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan...
Read moreApproval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director...
Read more